Instead of vaccinating with Dendritic Cells one could also aim at targeting DCs in vivo. In recent years many DC associated surface receptors have been characterized that can be exploited to target antigens to DCs. Antibodies coupled to antigen directly or to PLGA nanoparticles containing antigens and adjuvant can be exploited to get these vehicles be bound by DC, taken up, and degraded such that antigen is crosspresented on MHC molecules for antigen presentation to T cells.
For further reading:
Cruz LJ, Rueda F, Tacken P, Albericio F, Torensma R, Figdor CG. Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells. Nanomedicine (Lond), 2012. 7(10): 1591-610.
Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 2012. 119(10): 2284-92.
Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, Lambeck AJ, Figdor CG. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood, 2011. 118(26): 6836-44.
Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: Steps towards cost effective vaccines. Seminars in immunology, 2011. 23(1): 12-20.
Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol, 2007. 7(10): 790-802.